Targeted markets IBL-America serves autoimmune, brain research, endocrinology, infectious disease, neuroscience, oncology and tumor markers, indicating multiple high-demand segments for diagnostic kits and antibodies. Sales opportunities exist in hospitals, academic research labs, and biotech firms focusing on these areas.

Strategic partnerships Collaborative potential with sister company KMI Diagnostics for CLIA-compliant endocrinology and neurotransmitter testing, enabling bundled offerings, shared sales channels, and expanded service coverage to clinics and research centers.

Recent expansions Product launches in ELISA kits for Angiotensinogen and monoclonal antibodies against Titin, plus sLEP-R and AGT assays, signaling a growing catalog and cross-sell opportunities to existing customers requiring assay development and reference materials.

Event engagement Active participation in Kidney Week 2025 positions IBL-America to generate leads among nephrology practitioners and researchers; leverage event presence to showcase new ELISAs and antibodies to a targeted audience.

Tech & reach Digital marketing footprint includes Google Ads and Facebook, with technical support staff ready to engage; leverage this to drive demand generation, lead capture, and education around niche diagnostic reagents, expanding into mid-size biotech and CROs.